Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Other Non-Current Liabilities (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Other Non-Current Liabilities for 14 consecutive years, with $2.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Liabilities rose 300.76% year-over-year to $2.1 million, compared with a TTM value of $2.1 million through Dec 2025, up 300.76%, and an annual FY2025 reading of $2.1 million, up 300.76% over the prior year.
  • Other Non-Current Liabilities was $2.1 million for Q4 2025 at Fate Therapeutics, up from $410000.0 in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $24.6 million in Q3 2021 and bottomed at $320000.0 in Q2 2025.
  • Average Other Non-Current Liabilities over 5 years is $4.0 million, with a median of $1.2 million recorded in 2024.
  • The sharpest move saw Other Non-Current Liabilities crashed 96.75% in 2022, then surged 300.76% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $24.2 million in 2021, then plummeted by 84.02% to $3.9 million in 2022, then plummeted by 81.84% to $701000.0 in 2023, then decreased by 24.82% to $527000.0 in 2024, then soared by 300.76% to $2.1 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for FATE at $2.1 million in Q4 2025, $410000.0 in Q3 2025, and $320000.0 in Q2 2025.